[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Carsten SchwarzJutta BendHelge HebestreitMichael HogardtChristian HügelStephan IllingJochen G MainzErnst RietschelSebastian SchmidtBernhard Schulte-HubbertHelmut SitterMarc Oliver WielpützJutta HammermannIngo BaumannFrank BrunsmannDoris DieninghoffErnst EberHelmut EllemunterPatience EschenhagenCaroline EversSaskia GruberAssen KoitschevJulia Ley-ZaporozhanUta DüesbergHans-Joachim MentzelThomas NüßleinFelix C RingshausenLudwig SedlacekChristina SmacznyOlaf SommerburgSivagurunathan SutharsanRalf-Peter VonbergAnn-Katrin WeberJovita ZerlikPublished in: Pneumologie (Stuttgart, Germany) (2024)
Cystic Fibrosis (CF) is the most common autosomal recessive genetic multisystemic disease. In Germany, it affects at least 8000 people. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the airway epithelial lining fluid which leads to reduction of the mucociliary clearance.Even if highly effective, CFTR modulator therapy has been available for some years and people with CF are getting much older than before, recurrent and chronic infections of the airways as well as pulmonary exacerbations still occur. In adult CF life, Pseudomonas aeruginosa (PA) is the most relevant pathogen in colonisation and chronic infection of the lung, leading to further loss of lung function. There are many possibilities to treat PA-infection.This is a S3-clinical guideline which implements a definition for chronic PA-infection and demonstrates evidence-based diagnostic methods and medical treatment in order to give guidance for individual treatment options.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- lung function
- biofilm formation
- acinetobacter baumannii
- healthcare
- genome wide
- copy number
- physical activity
- stem cells
- oxidative stress
- chronic obstructive pulmonary disease
- intellectual disability
- multidrug resistant
- drug resistant
- middle aged
- combination therapy
- cell therapy